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I shall begin with two axioms and a few definitions and, subsequently, offer conclusions and a few
words to the medical lexicon. Axiom # 1-there
is no such thing as a CV A. In the year 1974,
with cerebral angiography widely available and with
computerized axial transverse tomography coming
into its own, CVA can only stand for "confused
vascular analysis." Axiom #2-the best time to
treat a stroke is before it happens or at the very
least, before it significantly disables the patient.
Ultimately, there are two fundamental kinds
of stroke: cerebral infarction or ischemia and cerebral hemorrhage. The first relates to a focal cerebral
dysfunction due to transient or persistent insufficiency of blood in a given cerebral vascular territory.
The second relates to the often massive escape of
blood into the brain parenchyma, the subarachnoid
space, or both locations. From a practical standpoint, a lumbar puncture which fails to reveal blood,
and particularly xanthochromia, effectively rules out
almost all cerebral hemorrhages and suggests the
process of cerebral ischemia or infarction. The two
major kinds of stroke can be differentiated clinically
without too much difficulty. On the other hand,
the problems of etiology, pathogenesis, and management continue to challenge the clinician. Since
strokes due to cerebral ischemia and/ or infarction
account for 75% or more of all observed strokes,
and because of the preponderance of strokes of this
variety and the limits of space, we will confine our
attention here entirely to the problem of cerebral
ischemia and infarction.
If one is to classify strokes due to cerebral
ischemia, one may do so in terms of the nature
and duration of the episode, on the one hand, and
the vascular territory of involvement, on the other
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hand. When an episode of focal cerebral dysfunction
occurs which is related to a given vascular territory,
persists for minutes to at most 12-24 hours, and
then vanishes completely, we say that the patient
has had a transient ischemic cerebral attack. If the
episode involves the vision of one or the other eye
(patients often state that it seemed as though a shade
was drawn across the vision of the eye), we state
that the patient has had a transient retinal ischemic
attack or amaurosis fugax. Onset over a period of
a few seconds to a few minutes characterizes these
episodes. If an episode develops either quickly or
over a period of minutes to hours and if the focal
deficit persists for many days and then largely but
not completely clears, we say that the patient has
had a transient ischemic episode with incomplete
recovery. From a pathogenic and treatment standpoint, the transient ischemic episodes and transient
ischemic episodes with incomplete recovery are
considered to be a single entity. If the focal deficit
appears over minutes to hours or sometimes even
days and persists, severely disabling the patient, we
say that the patient has suffered from a completed
stroke. In this situation, cerebral infarction, characteristically, is the underlying cerebral pathology.
Quite frankly, most neurologists in the field
at this time can point to no satisfactory treatment
for the completed stroke, except for good medical
care with attention to cardiopulmonary function,
management of blood pressure, withholding of oral
intake, and treatment entirely by intravenous fluids
during the acute period, particularly when the patient is mildly obtunded. These efforts have stood
the test of time. More specific therapy, such as
stellate ganglion block and C0 2 inhalation, as well
as streptokinase and urokinase, have fallen by the
wayside, some buried by their own initial advocates.
Nevertheless, the search must go on. In only one
area, that of stroke in evolution involving the brain
stem, has a specific form of therapy, anticoagulation,
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reduced mortality and morbidity to a degree-tenfold-which causes the Mayo group to advocate
its use with vigor in this specific instance.
Ischemic strokes are also defined in terms of
territory of presumed blood vessel involvement. The
two major territories are those of the carotid middle
cerebral-anterior cerebral system and the vertebrobasilar system. Carotid territory dysfunction is characterized by one or more of the following: ipsilateral, transient or rarely persistent visual loss due
to the fact that the ophthalmic artery is the first
branch of the carotid artery, contralateral weakness,
contralateral cortical sensory dysfunction, contralateral hemianopia, and in almost all of the righthanded individuals and in some 60% of left-handed
individuals, aphasia or dysphasia-the impairment
of the faculty of language when the left internal
carotid artery territory and left cerebral hemisphere
are involved. The words of the psalmist, "If I forget
thee, O' Jerusalem, let my right hand forget its
cunning and let my tongue cleave to the roof of my
mouth," characterize the classic dominant carotid
territory lesion.
Strokes due to vertebrobasilar involvement
rarely give rise to the classic crossed syndromes so
familiar in neuroanatomy texts, such as Weber's
syndrome, characterized by an ipsilateral third nerve
palsy and a contralateral hemiplegia. More often, one
or more of the following characterize ischemia in
the vertebrobasilar territory: alternating hemiparesis ,
ataxia, diplopia, dysarthria, hiccup, alterations in
respiratory pattern, nausea and vomiting, and pupillary changes.
Many things can cause transient or persistent
focal cerebral or retinal ischemia. Particularly when
ischemia is encountered in younger individuals, one
may suspect a primary c ardiac source involving
the valves as in rheumatic endocarditis or verrucous
endocarditis, left atrial thrombosis in rheumatic
heart disease with mitral stenosis and atrial myxoma.
Changing pulses and/ or chest pain should suggest a
dissecting aneurysm. Atrial fibrillation should always
suggest a primary cardiac source. A variety of systemic diseases including polycythemia, thrombotic
thrombocytopenic purpura, idiopathic thrombocytosis, and granulomatous angiitis, as well as disseminated intravascular coagulation should be thought of
in all cases; but the garden variety of transient or
persistent stroke due to focal cerebral ischemia, as
seen in the hospital, usually appears in a seemingly
healthy male at an average age of 62. The incidence
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of what is still fashionably called "cerebral thrombosis" in this patient population approaches 1% per
year in the age group 65-74. Almost 40% of these
patients have a history of increased blood pressure,
20% a history of diabetes, and at least 50% will give
a history of a previous transient cerebral ischemic
episode. Hypertension, diabetes, and previous TIA's
constitute the triad of the stroke-prone profile;
indeed, 30-37% of patients with transient ischemic
episodes will exhibit a full-blown completed stroke
within five years if untreated.
Our New York University (NYU) study of
the surgical treatment of transient and persistent
focal cerebral ischemia revealed approximately onethird of the patients with transient ischemic attacks ,
one-third with transient ischemic attacks and incomplete recovery, and one-third with completed strokes.
Arteriographic studies had borne out the fact , first
extensively studied by Hutchinson and Yates , that
the garden variety of transient or persistent focal
cerebral ischemia is related more to observable
extracranial atheromatous arterial disease, particularly in the carotid arteries than to primary intracranial occlusive disease and indeed, more to stenosis than to occlusion.
Various studies have defined the preferred sites
of atheromatous disease in the surgically approachable areas of the brachiocephalic system. Predominance of the carotid bifurcation involvement is apparent with stenosis of greater than 30% being
present in more than one-third of all right and
one-third of all left carotid arteries. Frank occlusion
is much less common. In the intracranial circulation,
observable stenotic lesions in the carotid territory
fall tenfold. The values for occlusion in the distal
carotid artery are inflated because in many cases
occlusion is taken to represent propagation of clot
from the origin of the internal carotid artery. Proximal vertebral artery involvement has been seen in
approximately 20% of all vertebral origins on the
right and left. Considerably less often, but probably
symptomatically much more important, is stenosis
which is seen distally in the vertebrobasilar system.
There is no clear-cut relationship between
frank carotid occlusion and the degree of neurological deficit. Another problem encountered is that
patients often do not present with a single high
grade stenotic lesion in the artery appropriate to
their cerebral symptoms; rather they present with a
complex mixture of arterial lesions which may give
rise to the exact same symptomatology.
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In our NYU experience with 400 patients, we
tried to group all of the cases into a meaningful
framework. It is understood that every patient's
vascular fingerprint is individual and that there are
almost as many patterns of lesions as there are
symptomatic patients. It was interesting that when
we classified a lesion as a lesion , if the stenosis occupied more than 30% of the vascular lumen in
any x-ray plane, 17 % of the patients showed no
lesions which occupied 30% or more of a vessel
lumen after four-vessel angiqgraphy. The existence
of this pleomorphic pattern of vascular lesions,
paired with the fact that 50% of all individuals
over the age of 50 have a major stenosis of at least
one of the four major vessels (two carotid and two
vertebrals, all leading to the brain), and that only
10% ultimately become symptomatic, offered numerous roadblocks to our eventual understanding
of the pathogenesis of at least most of the carotid
territory transient and persistent strokes.
Until the 1960's, it had been customary to
attribute the patient's symptoms to the degree of
stenosis or occlusion of the vessel developing by
one or more pathogenic processes, which led to
marked luminal compromise and then , presumably,
to symptoms which developed in proportion to the
degree of collateral circulation possessed by the
patient. Surgical studies compared with angiographic
observations, however, began to question this
stenotic theory of pathogenesis of strokes. A new
concept of pathogenesis, best characterized as the
embolic theory, arose.
The sources of arteri al emboli from lesions,
which may occupy less than 30% of the vascular
lumen formerly considered to be insignificant, were
as follows : necrotic plaque, clot from ulcer, and
platelet emboli from ulcer. Ulcerations can easily
be seen on angiography, in the initial phases associated often with high grade stenosis, and the dye
can also be seen hung up in the ulcer crater. Distal
propagation of thrombus , significantly compromising
the internal carotid lumen , can be seen. Radiologic
evidence from NYU disclosed 24 ulcerative and 22
irregular lesions at the origin of the internal carotid
arteries of the neck in the cerebral angiograms of
71 patients with history of cerebral vascular occlusive disease . Further, the incidence of middle
cerebral branch occlusion associated with either
irregular or ulcerative lesions of the extracranial
carotid arteries was 33%, compared to 16% of
patients with angiographically "normal" or smoothly

stenosed extracranial carotid arteries. More and
more evidence, therefore, implicates the process of
arterial-arterial embolization as a major one, particularly in transient and often in persistent focal
cerebral ischemia.
Thus we have a process of arterial-arterial
embolization as distinct from cardiac-cerebral artery
embolization, which apears to be a major pathogenic factor in ischemic strokes toward which treatment should be aimed before the stroke occurs,
when we are warned by the presence of a transient
episode. Since the term embolus is overextended
and usually implies cardiac source, muddying our
thinking about cerebral ischemia, I have Jong felt
that to require the term "cerebral embolus" to include in its embrace the widespread process of arterial embolization would be like asking a mouse
to extend its amorous interests to an elephant; it
would confound confusion where too much confusion already exists. I have proposed, therefore,
the acronym, "artarem," to describe an embolus
which arises in an artery (art-) and lodges in a
distal artery ( -ar-) by a process of embolization
(-em) . The process can be described as being
artaremic. On the other hand , if the embolus, from
clinical evidence, appears to arise from the heart,
the term "cardiarem" will serve, and the process of
heart-to-artery embolization might be described as
"cardiaremic." Adjectival modifiers such as cerebral
fibrinoplatelet artarem or myxomatous cerebral cardiarem could give rise to further diagnostic precision.
Having noted angiographic and operative evidence of the artaremic process, research began for
a safe medication which could delay or inhibit the
first step in fibrinoplatelet emboli. Surgical studies had
already clearly revealed that the neck lesion often
was related to visual and cerebral symptoms since
these symptoms disappeared after surgery, whereas
control patients who were not surgically treated with
known similar les ions often developed stroke or
permanent visual defect. The experience of the
Cooperative Study of Extracranial Arterial Occlusion showed a tenfold reduction in the appearance
of frank stroke in the territory of the operated
artery in the neck. There can be no doubt, therefore,
that the source of the patient's difficulty was most
often in the prominent lesion at the carotid bifurcation. Surgery, however, has its drawbacks and random studies of surgery have failed to precisely define
the role of arterial surgery.
Our own NYU random study reveals one rea-
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son for the confusion. In patients who were not
randomized, the nonsurgical patients showed a considerably smaller initial long-term survival than the
surgical patients, suggesting a significant measure
of surgical selection. Where the patients were randomized, long~term survival was equal in both
groups; initial surgical mortality, however, was significantly greater.
Our figures show that in patients with full
recovery from transient cerebral ischemic attacks,
surgical mortality is down to 3% and long-term
survival is greater than in the nonsurgical group
(numbers too small for statistical significance).
Transient ischemic attacks in patients with incomplete recovery are characterized by a greater degree
of surgical mortality; but in the proportion surviving, a larger percentage survived five years. The
other major point of the surgical study was that
in patients with completed stroke, surgical mortality
is prohibitive, particularly in patients who are obtunded, and long-term survival is significantly better
in the nonsurgical group. Mortality over the long
term, however, is not simply a function of cerebral
vascular disease. Asrnciated atherosclerotic disease
is characteristic of this group of patients. While the
major cause of death in the postoperative period
after surgery is stroke, over the long term, cardiac
causes account for as many deaths as stroke, and
the number of deaths in the surgical and the nonsurgical series approach one another.
Since stroke surgery is prophylactic, the major
question remains-will stroke surgery in selected
patients significantly diminish the proportion of
stroke and significantly improve survival? No data
from randomized studies have yet settled this issue
completely satisfactorily. Thus, the search has gone
on for safe medications which will depress the tendency for fibrinoplatelet emboli to form on ulcerated
or irregular plaques. Obviously nothing can be done
for the initial process of disengorgement of gummatous and cholesterol material from the broken
down plaque. Anticoagulants have proven to be
successful in depressing the number of transient
ischemic episodes; however, anticoagulants can be
given only to a reliable, stable patient population,
and such therapy would be much more successful
in Rochester, Minnesota for Dr. Millikan's and Dr.
Whisnaqt's patients than for our patients at Bellevue
Hospital.
In the 1960's, Frasier Mustard's group in
Canada (1, 2) noted inhibition of the platelet
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aggregation release reaction by sulfinpyrazone. Subsequent studies have shown that anti-inflammatory
drugs, such as butazoladine derivatives and aspirin,
the pyridopyramidine compounds such as Persantine® and the tricyclic antidepressant drugs, have
an effect on platelets. The most profound inhibition
of ADP or collagen-induced platelet aggregation
is shown by aspirin . In the in vitro studies, 37% of
serotonin is released with no aspirin, as compared
to no release with aspirin. A tenfold increase in
ADP reveals that aspirin can no longer be effective
against aggregation, but that there is continuing
inhibition of serotonin release. Similarly, aspirin
inhibits connective tissue induced aggregation as
well as serotonin release from platelets. This effect
of aspirin is not confined only to the test tube, but
it has been shown in dogs that arterial thrombus
is retarded when the intimal surface of an artery
is mechanically or chemically damaged and similar
results have been shown after endarterectomy in
patients receiving aspirin ( 3) . While it is known
that as little as 5 gr of aspirin may depress the
aggregation release reaction for as long as five days
in man, as judged by the epinephrine challenge to
platelet rich plasma as well as with most in vitro
tests, this association of inhibition of aggregation
is not clearly related to observed inhibition of transient ischemic episodes. It has been noted, however,
that aspirin will stop transient retinal ischemic attacks, amaurosis fugax. We have been able to follow
a most instructive patient at NYU who had as many
as nine attacks daily of amaurosis fugax, with response to increasing doses of aspirin in terms of
attacks and effect on platelet aggregation release
reaction. This unusual patient demonstrated that
the optimal dose of aspirin for amaurosis fugax
appears to be 5 gr qid. A retrospective study recently
published in Stroke by Dy ken ( 3) shows a relative
diminution of transient cerebral ischemic attacks
in aspirin-treated patients. It is of interest that in
some of his cases the attacks responded better to
four aspirin tablets per day than to two. Prospective
studies of aspirin, directed toward not only the
question of aspirin inhibition of transient attacks,
but also to the more important question of prophylaxis against completed stroke, are in process in
the United States and in Canada and no definitive
statement will be made on this subject for at least
another year.
The judicious mixture of surgical therapy and
prophylactic therapy with a safe platelet antiag-
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gregant appears at this time to be the best combination of approaches to the axiom: the best time to
treat a stroke is before it happens.

2. SMYTHE HA, 0GRYZLO MA, MURPHY EA, M USTARD
JF: The effect of sulfinpyrazone (anturan) on platelet
economy and blood coagulation in man. Can Med Assoc
I 92 : 818, 1965.
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